Session » (0096–0116) Antiphospholipid Syndrome Poster
- 9:00AM-11:00AM
-
Abstract Number: 0099
Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases
- 9:00AM-11:00AM
-
Abstract Number: 0105
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
- 9:00AM-11:00AM
-
Abstract Number: 0104
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 0103
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
- 9:00AM-11:00AM
-
Abstract Number: 0108
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
- 9:00AM-11:00AM
-
Abstract Number: 0111
Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0107
Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020
- 9:00AM-11:00AM
-
Abstract Number: 0116
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
- 9:00AM-11:00AM
-
Abstract Number: 0112
Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome
- 9:00AM-11:00AM
-
Abstract Number: 0110
Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss
- 9:00AM-11:00AM
-
Abstract Number: 0101
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0096
Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
- 9:00AM-11:00AM
-
Abstract Number: 0109
Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0114
Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
- 9:00AM-11:00AM
-
Abstract Number: 0106
Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds
- 9:00AM-11:00AM
-
Abstract Number: 0098
Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”
- 9:00AM-11:00AM
-
Abstract Number: 0115
Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0113
Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0100
The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
- 9:00AM-11:00AM
-
Abstract Number: 0102
The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome Patients
- 9:00AM-11:00AM
-
Abstract Number: 0097
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)